Celltrion Revenue

In the year 2024, Celltrion had annual revenue of 3.56T KRW with 63.45% growth. Celltrion had revenue of 1.06T in the quarter ending December 31, 2024, with 178.01% growth.

Revenue

3,557.30B

Revenue Growth

+63.45%

P/S Ratio

9.47

Revenue / Employee

1.49B

Employees

2,391

Market Cap

33.69T

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	3,557.30B	1,380.87B	63.45%
Dec 31, 2023	2,176.43B	-107.54B	-4.71%
Dec 31, 2022	2,283.97B	390.57B	20.63%
Dec 31, 2021	1,893.40B	44.29B	2.39%
Dec 31, 2020	1,849.12B	720.66B	63.86%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Samsung Biologics	4,547.32B
ALTEOGEN	102.85B
Yuhan	2,067.79B
SK Biopharmaceuticals	547.60B
HLB Co., Ltd.	68.13B
PharmaResearch	350.12B
Peptron	3.15B
LigaChem Biosciences	125.90B

Revenue Rankings

Celltrion News

12 days ago - Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing ... - GuruFocus
22 days ago - Shilpa Medicare settles Celltrion arbitration case with $3.4 million agreement - Business Upturn
6 weeks ago - Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025 - Financial Post
2 months ago - Celltrion’s Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada - Financial Post
5 months ago - FDA approves Celltrion's biosimilar of J&J's Stelara - Seeking Alpha
5 months ago - Health Canada approves Celltrion’s Omlyclo™ (CT-P39), the first and only omalizumab biosimilar in Canada - Financial Post

More News